COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening for Fabry Disease in a Pediatric Population at Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02152189
Recruitment Status : Completed
First Posted : June 2, 2014
Last Update Posted : December 13, 2017
Sponsor:
Information provided by (Responsible Party):
Markus Ries, MD PhD MHSc FCP, University Hospital Heidelberg

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the frequency of Fabry disease in children with chronic abdominal pain or chronic pain in the extremities

Condition or disease Intervention/treatment
Chronic Pain in the Extremities Chronic Abdominal Pain Fabry Disease Other: Screening for Fabry disease

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1422 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Study Start Date : May 2014
Actual Primary Completion Date : May 2017
Actual Study Completion Date : November 2017

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Screening population Other: Screening for Fabry disease


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Prevalence of Fabry disease [ Time Frame: day 1 ]

Secondary Outcome Measures :
  1. Prevalence of Fabry disease in predefined sub-populations [ Time Frame: day 1 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Children with rheumatological disorders or chronic abdominal pain
Criteria

Inclusion Criteria:

  • Age below 18 years

  • One of the following criteria:

    • Diagnosis or suspicion of a rheumatological disorder with recurrent complaints for more than 6 months
    • Chronic, recurrent abdominal pain for more than 6 months
  • Planned blood sample for routine diagnostics
  • Written informed consent

Exclusion Criteria:

- Patient and/or the patient's parent(s) or legal guardian(s) are unable to understand the nature, scope, and possible consequences of the screening.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02152189


Locations
Layout table for location information
Germany
Zentrum für Kinder- und Jugendmedizin
Heidelberg, Germany
Sponsors and Collaborators
University Hospital Heidelberg
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Markus Ries, MD PhD MHSc FCP, Professor, University Hospital Heidelberg
ClinicalTrials.gov Identifier: NCT02152189    
Other Study ID Numbers: Fabry screening 02202014
S-084/2014 ( Other Identifier: IRB Heidelberg )
First Posted: June 2, 2014    Key Record Dates
Last Update Posted: December 13, 2017
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Chronic Pain
Abdominal Pain
Pain
Neurologic Manifestations
Signs and Symptoms, Digestive
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders